Updated August 2026
NAD+ Dosage: Human Trials, IV Protocol, Oral Research, and Safety
Research note: NAD+ is a dinucleotide coenzyme, not a peptide. This page covers direct administration of oxidized nicotinamide adenine dinucleotide and does not substitute doses from NR, NMN, niacin, nicotinamide, NADH, or NADPH. The complete protocol below is a clinical-research framework — not a self-treatment or home-infusion plan.
No single NAD+ dose is established across routes or purposes. Direct human studies have used 10–750 mg IV in different populations, formulations, rates, and endpoints.
Strongest direct clinical dataset: 10 mg IV once daily for 7 days (180 hospitalized adults with ischemic-cardiomyopathy HF; ~40–60 min infusion). A 750 mg / 6-hour study best documents pharmacokinetics. A commercial 500 mg series averaged ~97 minutes and was poorly tolerated in all six recipients.
Common 250–1,000 mg wellness infusions and SC/IM charts are conventions — not a validated dose range. Route, rate, and sterile-product quality matter as much as milligrams.
NAD+ dosage in 30 seconds
| Question | Research summary |
|---|---|
| Compound class | Pyridine dinucleotide coenzyme — not a peptide |
| ≠ precursors | NR, NMN, niacin, NAM, NADH, NADPH |
| Strongest IV clinical anchor | 10 mg once daily × 7 days (HF RCT) |
| Highest controlled IV exposure | 750 mg once over 6 hours |
| 500 mg commercial series | Poorly tolerated when infused faster |
| Validated SC / IM | Not located |
| Anti-aging / addiction dose | Not established |
| Main acute concern | Rate-related symptoms + sterile IV risks |
What is NAD+?
NAD+ is the oxidized member of the NAD+/NADH redox pair and a substrate for sirtuins, PARPs, CD38/CD157, and SARM1. Biological importance does not prove that exogenous NAD+ improves energy, aging, cognition, recovery, or disease outcomes.
Material sold as “NAD+” may be free acid/zwitterion, sodium salt, hydrate, lyophilized injectable, solution, capsule, or proprietary formulation. Nominal fill mass ≠ assay-corrected beta-NAD+.
Identity gate
Confirm direct beta-NAD+ — not NR/NMN, NADH, LNAD+, or food-grade powder
Matches the subject of this page
Oxidized nicotinamide adenine dinucleotide coenzyme — not a peptide. Confirm identity, NAD+-equivalent assay, salt/hydrate basis, sterility, and endotoxin before any parenteral research use.
NAD+ is not interchangeable with its neighbors
| Name | What it is | Assign dose to direct NAD+? |
|---|---|---|
| NAD+ | Oxidized dinucleotide | This page’s subject |
| NADH | Reduced redox partner | No |
| NR / NMN | NAD+ precursors | No |
| Niacin / NAM | Vitamin B3 forms / salvage precursors | No |
| LNAD+ | Proprietary oral NAD+/PEG product | Not equivalent to ordinary NAD+ |
Current research and regulatory status
There is no standardized US prescribing label for direct NAD+ infusion. Chinese heart-failure trials used a nationally registered injectable coenzyme I product — that history does not create a US indication or analytical equivalence for compounded US products.
FDA has warned that food-grade NAD+ is unsuitable for sterile compounding without appropriate processing. A 2026 warning letter described patients with hypotension, shaking, and body aches after compounded NAD+; an unopened vial measured 3,360 EU/mL endotoxin.
NAD+ dosages used in human research
Only studies that directly administered NAD+ are included — not precursor trials.
Human evidence status
Direct NAD+ only — fragmented across IV, oral, and clinic contexts
- Standardized US prescribing dose
- None
- Strongest direct clinical dataset
- 10 mg IV once daily × 7 days (n=180 HF RCT)
- Second HF RCT
- 50 mg IV once daily × 7 days (smaller; main LVEF/NT-proBNP NS)
- Best direct PK study
- 750 mg IV over 6 hours (~2 mg/min)
- Commercial 500 mg × 4 days
- Poorly tolerated when infused faster (all 6 symptomatic)
- Proprietary oral LNAD+
- 500 mg reported dose QID × 5 days (+ extras) — biomarker only
- Validated human SC / IM schedule
- Not located
- Validated anti-aging / addiction dose
- Not established
- Human weight-based formula
- Not established
Direct-human studies at a glance
| Study | Amount | Route / duration | Main limit |
|---|---|---|---|
| Yu et al., 2026 | 10 mg in 100 mL daily | IV × 7 days | Single-center HF population; short exposure |
| Pei et al., 2024 | 50 mg in 50 mL daily | IV × 7 days | Small; main LVEF/NT-proBNP comparisons NS |
| Grant et al., 2019 | 750 mg | IV over 6 hours once | n=8 active; metabolome only |
| Reyna et al., 2026 | 500 mg in 500 mL daily | IV × 4 days (mean ~97 min) | n=6; all symptomatic; retrospective |
| Kornilov et al., 2026 | Reported 500 mg doses QID (+ extras) | Oral LNAD+ × 5 days | Proprietary; RBC-dominant biomarker |
In the 10 mg HF trial, one-month LVEF between-group differences reached P < 0.05; NT-proBNP, MACCE, and hospitalization differences did not. This is disease-specific evidence — not an anti-aging or wellness dose.
Reported direct-human dosage landscape
The 10–750 mg interval describes heterogeneous studies — not a validated therapeutic range. Wellness “250 starter / 500 standard / 750–1,000 intensive” ladders were not located as randomized dose-finding results.
Evidence split
Published direct-NAD+ research vs wellness / practitioner conventions
Published direct-NAD+ research
Route- and indication-specific
- IV amounts studied
- 10, 50, 500, or 750 mg in distinct studies
- Strongest RCT
- 10 mg IV daily × 7 (n=180 HF)
- PK pilot
- 750 mg over 6 hours
- Oral
- One proprietary LNAD+ 5-day QID trial
- SC / IM
- No validated direct-human schedule
- Established wellness benefit
- None
Current wellness / practitioner conventions
Anecdotal — not clinical guidelines
- IV session
- Commonly 250–1,000 mg (some claim higher)
- “Loading”
- 3–5 sessions or 7–14-day series
- Infusion time claims
- Often 2–8 hours to tolerance
- SC charts
- Often 25–200 mg daily–several×/week
- IM charts
- Often 50–200 mg weekly
- Origin
- Historical addiction schedule + vial convenience
Infusion rate may be as important as total dose
These are not randomized rate-comparison data, but the pattern is compatible with rate-dependent tolerability. A rate tolerated in one study should not be assumed safe for another product or participant.
Rate vs dose
Published infusion contexts — not a randomized rate matrix
Approx. NAD+ rate
≈0.17–0.33 mg/min
Concentration / duration
0.1 mg/mL · 40–60 min (100–200 mL/h)
Tolerability: 1 minor dizziness / 90 active. Compatible with rate-dependent symptoms — populations and products also differed.
Complete evidence-anchored research protocol (10 mg HF replication)
Most defensible replication anchor: the 10 mg/day ischemic-cardiomyopathy trial (largest direct-NAD+ RCT) with concentration, carrier volume, initial rate, titration interval, maximum rate, and follow-up preserved — plus stronger product characterization and safety monitoring.
Active exposure: 10 mg assay-corrected beta-NAD+ in 100 mL dextrose or saline (compatibility validated) once daily × 7 days. Start 100–120 mL/h, stepwise increases ≤ every 15–30 min if criteria met, max 200 mL/h. No within-participant dose escalation. Food-grade/RUO powder is not acceptable.
10 mg HF research framework
Assay-corrected 10 mg / 100 mL · 100–200 mL/h · 7 days · no dose escalation
1–7
10 mg in 100 mL · 100–120 → max 200 mL/h
≈40–60 min; exact duration recorded; no within-participant dose escalation
Disease-specific cardiac research replication — not a wellness or home-infusion schedule. Food-grade / RUO powder is not acceptable.
The 750 mg Grant protocol can be a separate metabolism study — do not graft it onto the 10 mg efficacy trial. Hold/stop rules cover chest symptoms, hemodynamics, fever/rigors (possible endotoxin), and same-lot event clusters.
Concentration and reconstitution math
Research-pharmacy arithmetic only — not a self-injection authorization. Concentration = assay-corrected NAD+ mass ÷ final validated volume. Delivery rate (mg/min) = concentration × pump mL/h ÷ 60.
Pharmacy arithmetic
Infusion rate and stock-volume examples — batch validation required
Bag concentration
Pump rate
Delivery
0.200 mg/min
12.0 mg/h at 120 mL/h · 0.1 mg/mL
Published admixture arithmetic
| Protocol | Amount | Carrier | Concentration | Course |
|---|---|---|---|---|
| Yu HF | 10 mg | 100 mL | 0.1 mg/mL | 70 mg / 7 days |
| Pei HF | 50 mg | 50 mL | 1 mg/mL | 350 mg / 7 days |
| Reyna clinic | 500 mg | 500 mL | 1 mg/mL | 2,000 mg / 4 days |
| Grant PK | 750 mg | NR | Cannot calculate | 750 mg once |
Using 663.4 g/mol for characterized free zwitterion: 10 mg ≈ 15.1 µmol; 750 mg ≈ 1.13 mmol. Do not apply automatically to salts, hydrates, or proprietary formulations.
Preclinical NAD+ dosage
Rat myocardial I/R models used 5–20 mg/kg IV; a rat cerebral-ischemia model used 10 mg/kg intranasal. Animal mg/kg amounts must not be copied into a human schedule or casually converted by body-surface-area arithmetic.
How NAD+ may work
Redox cofactor cycling (NAD+/NADH), consumed-substrate pathways (sirtuins/PARPs/CD38/SARM1), and extracellular metabolism of infused NAD+ (rapid early disappearance; later metabolite rises) are under investigation.
“Direct to the bloodstream” is not the same as delivery to brain, muscle, or mitochondria. Plasma NAD, whole-blood total NAD, NAD+/NADH ratio, and tissue NAD are different endpoints.
Potential benefits: what has and has not been shown
Claim vs direct human evidence
| Claim | Current conclusion |
|---|---|
| Modest LVEF signal in ischemic-cardiomyopathy HF | Promising disease-specific signal needing multicenter replication |
| HF clinical events / hospitalizations | Not established |
| Raises plasma/urine NAD metabolites (750 mg) | PK evidence, not efficacy |
| Raises whole-blood total NAD (oral LNAD+) | Product-specific biomarker; no health outcome |
| Energy, aging, cognition, athletics, addiction | Not established |
NAD+ safety and side effects
Tolerability differs by protocol — dose alone does not explain differences. Rate, concentration, carrier volume, population, formulation, and product quality all matter.
Urgent signs (chest pain, trouble breathing, fever/rigors, hypotension, same-lot clusters) require immediate medical evaluation — do not simply slow and continue through a potentially serious reaction.
Safety monitoring
Rate, sterile quality, and fluid load — not milligrams alone
- 10 mg IV × 7 (HF RCT)
- 1 minor dizziness among 90 active; no notable liver/kidney/glucose signal reported
- 500 mg faster clinic infusion
- All 6: GI symptoms, ↑ HR, throat pain, congestion, chest pressure during infusion
- Product / sterile quality
- Endotoxin contamination documented in FDA warning-letter context — preventable manufacturing risk
- IV procedure risks
- Line infection, extravasation, fluid overload (esp. large bags), pump/calculation errors
Quality testing and storage
Release testing should include orthogonal identity, quantitative NAD+-equivalent assay, counterion/water, degradation profile, sterility, bacterial endotoxin, particulates, pH/osmolality, container compatibility, and potency-indicating stability. “99% HPLC purity” alone is insufficient.
Stability is formulation-specific. Do not assign a generic 14-/28-/90-day beyond-use period from a vendor blog.
Common claims vs evidence
Claim checker
Common NAD+ claims vs the evidence record
There is one standard NAD+ dose
False
Published direct-human protocols include 10, 50, 500, and 750 mg in different contexts. They are not one therapeutic range.
NAD+ dosage evidence ladder
Dosage evidence ladder
NAD+ dosing is not one cross-purpose protocol
| Level | What exists | Confidence |
|---|---|---|
| Standardized US prescribing dose | None | None |
| 10 mg IV daily × 7 | One 180-person randomized HF trial | Moderate, disease-specific |
| 50 mg IV daily × 7 | One small randomized HF trial | Low-to-moderate |
| 750 mg IV over 6 hours | 8 active participants (metabolome) | Low, mechanistic |
| 500 mg IV daily × 4 | 6 commercial clients (retrospective) | Very low |
| Proprietary oral LNAD+ QID × 5 days | Randomized product-specific biomarker trial | Moderate for RBC-dominant biomarker; low for benefit/transfer |
| SC and IM schedules | Vendor/practitioner charts only | Insufficient |
| Long-term maintenance / wellness loading | Conventions and historical case series | Insufficient |
NAD+ dosing is not established as one cross-purpose protocol. High-dose wellness, “loading,” detox, SC, IM, and indefinite maintenance schedules remain largely conventions.
Sports and anti-doping considerations
Under the 2026 WADA list, IV infusions totaling more than 100 mL in 12 hours are prohibited outside specified exceptions. A 500 mL wellness bag can create a methods violation regardless of whether NAD+ is named as a prohibited substance.
Bottom line
Direct NAD+ has more human data than many wellness compounds, but evidence remains fragmented. A 10 mg HF protocol, 50 mg HF pilot, 750 mg metabolome experiment, symptomatic 500 mg commercial series, and proprietary oral study cannot collapse into one “optimal dose.”
For research: rigorously characterized multicenter replication of the 10 mg trial plus separate dose-and-rate studies. For readers: state identity, sterile quality, carrier volume, rate, population, and endpoint alongside milligrams — and keep community protocols clearly separate from validated evidence.
Rate and sterile-product quality can matter as much as the milligram number. Food-grade / RUO material is not injectable research material.
Frequently asked questions
Is NAD+ a peptide?
No. NAD+ is a pyridine dinucleotide coenzyme. It has no amino-acid sequence and should not be assayed or described as a peptide.
What is the standard NAD+ dose?
There is no universal standard. Published direct-human IV protocols include 10 mg/day × 7, 50 mg/day × 7, 500 mg/day × 4, and one 750 mg six-hour exposure — each in a different research context.
What dose has the strongest human evidence?
The largest randomized direct-NAD+ study used 10 mg IV once daily for seven days in hospitalized ischemic-cardiomyopathy heart-failure adults. That does not establish 10 mg for wellness use.
Is NAD+ the same as NR or NMN?
No. NR and NMN are precursors. Their doses and results are not direct NAD+ evidence.
Is there a validated subcutaneous NAD+ dose?
No direct-human SC pharmacokinetic or controlled dose-finding schedule was located. Online 25–200 mg schedules are anecdotal.
Should NAD+ be dosed by weight?
Not on current human evidence. Direct-human studies used fixed doses; mg/kg amounts appear in animal research.
Does NAD+ slow aging?
No direct human trial has established slower aging, longer lifespan, or reduced age-related disease from administered NAD+.
Can research-use-only NAD+ be injected?
No. RUO analytical material does not establish injectable identity, potency, sterility, endotoxin, or clinical manufacturing quality.
Is NAD+ allowed in tested sport?
Check both substance and method. WADA’s IV-volume rule prohibits more than 100 mL in 12 hours outside specified exceptions, so a wellness infusion can be problematic even before substance classification.
Does NAD+ treat addiction or withdrawal?
Controlled evidence is inadequate. The frequently cited IV schedule comes from a 1961 uncontrolled report and should not replace evidence-based withdrawal care.
References
Yu X et al.
NAD+ in heart failure due to ischemic cardiomyopathy — RCT10 mg IV daily × 7 days; n=180.
Pei Z et al.
NAD+ in older patients with heart failure50 mg IV daily × 7 days; smaller RCT.
Grant R et al.
Plasma and urine NAD+ metabolome during 6-hour IV infusion750 mg over 6 hours; n=8 active.
Reyna K et al.
IV NAD+ versus NR — retrospective tolerability pilot500 mg × 4 days; all 6 NAD+ clients symptomatic.
Kornilov SA et al.
Oral LNAD+ RCT — whole-blood intracellular NADProprietary oral formulation; 5-day biomarker study.
FDA
Reminder: ingredients suitable for sterile compoundingFood-grade NAD+ unsuitable without appropriate processing.
WADA
2026 Prohibited ListIV volume methods rule (>100 mL / 12 h).
PubChem
Nadide, CID 5892Chemical identity and molecular weight.